Numab Therapeutics announces collaboration and option agreement with Kaken Pharma

Numab Therapeutics AG announced a collaboration and option agreement with Kaken Pharmaceutical Co., Ltd. for the identification of a multispecific antibody candidate for development in inflammatory disease.

Under the agreement, Kaken will obtain an option to conclude a license and co-development agreement after identification of lead candidate generated by Numab using its unique multispecific antibody technology platform. Kaken is to fully fund the research program. Further financial details are not disclosed.